This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- IL13R{alpha}2-Targeting Antibodies for Immuno-PET in Solid Malignancies
- Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects
- Targeted Alpha Therapy with [225Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies
- Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors
- Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer
- Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer
- Dosimetry in Radiopharmaceutical Therapy
- Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- Preclinical Characterization of the Radioimmunoconjugate 111In or 90Y-FF-21101 Against a P-Cadherin-Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
- Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
- Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617
- Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia
- Human Dosimetry of the N-Methyl-D-Aspartate Receptor Ligand 11C-GMOM
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
- Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
- Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors
- Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
- 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma
- Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor
- PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
- Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
- A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation
- Bone Marrow Dosimetry Using 124I-PET
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
- RADAR Commentary: Evolution and Current Status of Dosimetry in Nuclear Medicine
- Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
- Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
- Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma
- Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
- Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
- Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
- Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma
- Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
- MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
- Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy
- A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae
- High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
- Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer
- Toward Patient-Friendly Cell-Level Dosimetry
- Reduced Myelotoxicity with Sustained Tumor Concentration of Radioimmunoconjugates in Rats after Extracorporeal Depletion
- [177Lu]Pertuzumab: Experimental Therapy of HER-2-Expressing Xenografts
- Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
- Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma
- 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
- Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate
- Blood-Based Red Marrow Dosimetry: Where's the Beef?
- Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
- Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry
- Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen
- Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Thyroid Cancer
- Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Differentiated Thyroid Cancer After Stimulation with rhTSH
- A Phase I Trial Combining High-Dose 90Y-Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
- Dosimetry of Internal Emitters
- 188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial
- PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer
- Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison
- Bone Marrow Dosimetry and Safety of High 131I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer
- Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer
- Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases
- Adipocyte Spatial Distributions in Bone Marrow: Implications for Skeletal Dosimetry Models
- Radiation Dosimetry Results and Safety Correlations from 90Y-Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma: Combined Data from 4 Clinical Trials
- Total-Body and Red Marrow Dose Estimates
- Red Marrow Radiation Dose Adjustment Using Plasma FLT3-L Cytokine Levels: Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose for Radioimmunotherapy Patients
- Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
- Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
- Considerations of Marrow Cellularity in 3-Dimensional Dosimetric Models of the Trabecular Skeleton
- Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study
- Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
- Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)
- An Analytic Dosimetry Study for the Use of Radionuclide-Liposome Conjugates in Internal Radiotherapy
- Contribution to Red Marrow Absorbed Dose from Total Body Activity: A Correction to the MIRD Method
- Biologic Dosimetry of Bone Marrow: Induction of Micronuclei in Reticulocytes After Exposure to 32P and 90Y
- Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck
- Phase I Trial Results of Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas
- High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial
- Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
- High-Linear Energy Transfer (LET) {{alpha}} versus Low-LET {beta} Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model